<DOC>
	<DOCNO>NCT00024050</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Peripheral stem cell transplantation may able replace immune cell destroy chemotherapy . PURPOSE : Phase II trial study effectiveness chemotherapy follow peripheral stem cell transplantation treat patient myelodysplastic syndrome .</brief_summary>
	<brief_title>Chemotherapy Peripheral Stem Cell Transplantation Treating Patients With Myelodysplastic Syndrome</brief_title>
	<detailed_description>OBJECTIVES : - Determine non-relapse toxicity mortality day 100 1 year transplantation patient low intermediate-risk myelodysplastic syndrome treat busulfan , cyclophosphamide , allogeneic peripheral blood stem cell transplantation . - Determine incidence donor stem cell engraftment relapse-free survival patient treat regimen . - Determine incidence severity acute chronic graft-versus-host disease invasive fungal infection patient treat regimen . - Determine incidence relapse patient treat regimen . OUTLINE : Peripheral blood stem cell ( PBSC ) bone marrow harvest related unrelated compatible donor . PBSC select CD34+ cell . Patients receive oral busulfan every 6 hour day -7 -4 cyclophosphamide IV day -3 -2 . Allogeneic PBSC bone marrow infuse day 0 . As graft-versus-host disease prophylaxis , patient receive cyclosporine IV begin day -1 continue orally twice daily ( feasible ) day 51 follow taper . Patients also receive methotrexate IV day 1 , 3 , 6 , 11 . Patients follow day 100 , every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : A total 40 patient accrue study within 3 year .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis low intermediaterisk myelodysplastic syndrome Refractory anemia ( RA ) RA ring sideroblasts No advanced myelodysplastic syndrome ( i.e. , least 5 % blast marrow , 1 % blast peripheral blood , blast cerebrospinal fluid ) No poorrisk cytogenetics ( i.e. , abnormalities chromosome 7 complex abnormality ) HLAA , B , C , DRB1 , DQB1 compatible relate unrelated donor available Mismatch single HLAA , B , C , DRB1 , DQB1 allele allow PATIENT CHARACTERISTICS : Age : 65 Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : AST great 2 time normal Renal : Creatinine great 2 time upper limit normal Creatinine clearance least 50 % Cardiovascular : No cardiac insufficiency require treatment No symptomatic coronary artery disease Pulmonary : No severe hypoxemia ( pO2 less 70 mm Hg DLCO le 70 % predict ) No mild hypoxemia ( pO2 less 80 mm Hg DLCO le 60 % predict ) Other : No disease would limit life expectancy HIV negative Not pregnant nursing PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>refractory anemia</keyword>
	<keyword>refractory anemia ring sideroblast</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>